ZNTL icon

Zentalis Pharmaceuticals
ZNTL

Overview Fund Activity

145 hedge funds and large institutions have $314M invested in Zentalis Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 56 increasing their positions, 42 reducing their positions, and 21 closing their positions.

Holders
145
Holders Change
+3
Holders Change %
+2.11%
% of All Funds
2.11%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0.03%
New
26
Increased
56
Reduced
42
Closed
21
Calls
$262K
Puts
$48K
Net Calls
+$214K
Net Calls Change
-$893K

Top Buyers

1
Vanguard Group
1
Vanguard Group
Pennsylvania
$23.1M
2
DC
2
Decheng Capital
California
$12.6M
3
Morgan Stanley
3
Morgan Stanley
New York
$7.98M
4
Two Sigma Investments
4
Two Sigma Investments
New York
$4.3M
5
Two Sigma Advisers
5
Two Sigma Advisers
New York
$3.26M

Top Sellers

1
PBA
1
Paradigm Biocapital Advisors
New York
$0
2
EAM
2
Eventide Asset Management
Massachusetts
$35M
3
T. Rowe Price Associates
3
T. Rowe Price Associates
Maryland
$3.78M
4
Capital International Investors
4
Capital International Investors
California
$2.76M
5
T. Rowe Price Investment Management
5
T. Rowe Price Investment Management
Maryland
$5.42M
Name Market Value Shares Shares
Change 		Shares
Change %
MCMC
1
Matrix Capital Management Company
New Hampshire
$57.1M 13,959,973 – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$35.5M 8,676,723 -1,967,301 -18%
EAM
3
Eventide Asset Management
Massachusetts
$35M 8,547,896 -3,026,925 -26%
Vanguard Group
4
Vanguard Group
Pennsylvania
$23.1M 5,654,757 +1,256,132 +29%
BlackRock
5
BlackRock
New York
$19.7M 4,818,546 +172,788 +4%
Citadel Advisors
6
Citadel Advisors
Florida
$18.4M 4,502,913 +650,484 +17%
DC
7
Decheng Capital
California
$12.6M 3,070,442 +970,859 +46%
State Street
8
State Street
Massachusetts
$12.5M 3,052,392 -733,260 -19%
Morgan Stanley
9
Morgan Stanley
New York
$7.98M 1,950,722 +913,313 +88%
WP
10
Woodline Partners
California
$6.2M 1,517,077 +80,051 +6%
MB
11
MPM BioImpact
Massachusetts
$5.93M 1,450,000 -66,183 -4%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$5.46M 1,334,459 +32,222 +2%
T. Rowe Price Investment Management
13
T. Rowe Price Investment Management
Maryland
$5.42M 1,325,491 -1,993,595 -60%
Primecap Management
14
Primecap Management
California
$5.04M 1,232,340 +67,730 +6%
Two Sigma Investments
15
Two Sigma Investments
New York
$4.3M 1,052,398 +807,403 +330%
TCM
16
Tybourne Capital Management
Hong Kong
$3.93M 961,486 – –
T. Rowe Price Associates
17
T. Rowe Price Associates
Maryland
$3.78M 923,901 -2,565,808 -74%
Two Sigma Advisers
18
Two Sigma Advisers
New York
$3.26M 796,900 +695,900 +689%
Capital International Investors
19
Capital International Investors
California
$2.76M 675,371 -2,144,293 -76%
Renaissance Technologies
20
Renaissance Technologies
New York
$2.71M 661,682 +399,745 +153%
Dimensional Fund Advisors
21
Dimensional Fund Advisors
Texas
$2.56M 626,663 -96,993 -13%
Goldman Sachs
22
Goldman Sachs
New York
$2.53M 619,253 +287,253 +87%
Verition Fund Management
23
Verition Fund Management
Connecticut
$2.26M 552,820 -602,416 -52%
Bank of America
24
Bank of America
North Carolina
$2.08M 508,233 +32,277 +7%
JPMorgan Chase & Co
25
JPMorgan Chase & Co
New York
$2.03M 495,810 +437,189 +746%
1
2 3 4 5